Skip to main content
. 2013 Dec 16;2013:741403. doi: 10.1155/2013/741403

Table 2.

Frequencies of CYP2B6, CYP2C19, and ABCB1 polymorphisms in responders and nonresponders to treatment (n = 176)a.

Genotype Responders
(n = 61)
Nonresponders
(n = 115)
P value
CYP2B6
 A785G (*4)
  A/A 29 (47.5) 72 (62.6) 0.15
  A/G 26 (42.6) 35 (30.4)
  G/G 6 (9.9) 8 (7.0)
 G516T (*9)
  G/G 38 (62.3) 86 (74.8) 0.10
  G/T 19 (31.1) 27 (23.5)
  T/T 4 (6.6) 2 (1.7)

CYP2C19
 G651A (*2)
  G/G 27 (44.3) 63 (54.8) 0.21
  G/A 32 (52.5) 45 (39.1)
  A/A 2 (3.2) 7 (6.1)
 G636A (*3)
  G/G 53 (86.9) 105 (91.3) 0.14
  G/A 6 (9.8) 10 (8.7)
  A/A 2 (3.3) 0 (0)
 C3402T (*17)
  C/C 60 (98.4) 114 (99.1) 0.64
  C/T 1 (1.6) 1 (0.9)
  T/T 0 (0) 0 (0)

ABCB1 Genotype
 C1236T
  C/C 5 (8.2) 15 (13.0) 0.53
  C/T 30 (49.2) 49 (42.6)
  T/T 26 (42.6) 51 (44.4)
 G2677T
  G/G 22 (36.1) 26 (22.6) 0.03*
  G/T 21 (34.4) 63 (54.8)
  T/T 18 (29.5) 26 (22.6)
 C3435T
  C/C 30 (49.2) 39 (33.9) 0.02*
  C/T 20 (32.8) 63 (54.8)
  T/T 11 (18.0) 13 (11.3)

aNo available data on genotype for two subjects (1 responder and 1 nonresponder) due to methodological problems.

*Statistical significance set at P < 0.05; comparisons were performed by the Chi-square test or Fisher's exact test as appropriate.